This study was performed to investigate factors determining tumor pressure (TP) in hepatocellular carcinoma (HCC) and a correlation of pressure gradient between TP and portal vein pressure (PVP) with tumor spread. TP and hepatic tissue pressure (HTP) were measured in 70 patients who underwent hepatic resection for HCC. Changes in TP after hepatic artery occlusion (HAO) or portal vein occlusion (PVO) were observed. HTP was elevated with worsening chronic liver disease, and exhibited a significant positive correlation with PVP. The TP was significantly higher in the encapsulated and the nonnecrotic HCCs. The pressure gradient (TP-PVP) was significantly greater in the encapsulated HCCs, especially in those with microscopic portal vein invasion (vp) or intrahepatic metastasis (im). HAO caused a greater decrease in TP than did PVO, with the decrease being particularly marked in the encapsulated HCCs. The TP of HCC was found to be regulated mainly by the presence or absence of a tumor capsule or necrosis, and partly by the hepatic arterial flow and PVP. Our study suggests that TP increases with capsule formation and that the pressure gradient between TP and PVP may be a causal factor in the dispersement of tumor cells into the portal vein.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.510260205DOI Listing

Publication Analysis

Top Keywords

portal vein
16
pressure gradient
12
tumor pressure
8
pressure hepatocellular
8
hepatocellular carcinoma
8
tumor spread
8
encapsulated hccs
8
pressure
7
tumor
6
factors regulating
4

Similar Publications

Background: Current management of patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) depends on the degree of involvement of the major arterial and venous structures. The aim of this study was to evaluate 3D segmentation and printing to predict tumor size and vascular involvement of BR-PDAC to improve pre-operative planning of vascular resection and better select patients for neoadjuvant therapy.

Methods: We retrospectively evaluated 16 patients with BR-PDAC near vascular structures who underwent pancreatoduodenectomy (PD) with or without vascular resection between 2015 and 2021.

View Article and Find Full Text PDF

Aim Of The Study: To assess the serum level of Mac-2 binding protein glycosylation isomer as a potential biomarker for hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) cirrhotic patients.

Material And Methods: Ninety patients were separated into two groups for the current research. Group I consisted of 45 patients with HCV that resulted in liver cirrhosis but no HCC.

View Article and Find Full Text PDF

Objective: To evaluate the impact of intrahepatic portal vein branching (IHPB)-grade assessment using preoperative CT angiography (CTA) on the surgical procedure and prognosis prediction for dogs with an extrahepatic portosystemic shunt (EHPSS).

Methods: This study involved 146 client-owned dogs with EHPSS. The shunt morphology of EHPSS and IHPB grades was determined using CTA.

View Article and Find Full Text PDF

The development of surgical techniques, chemotherapy, biological agents, and multidisciplinary approaches have made patients with unresectable colorectal liver metastases eligible for surgery. Many strategies have been developed to allow patients for surgical resection (percutaneous portal vein embolization, liver venous deprivation, parenchyma-sparing liver surgery, reverse strategy, associating liver partition and portal vein ligation for staged hepatectomy, and liver transplantation), the only form of disease control and curative treatment.

View Article and Find Full Text PDF

In patients with synchronic liver colorectal metastasis, resection of the primary tumor and liver metastases is the only potentially curative strategy. In such cases, there is no consensus on whether resection of the primary tumor and metastases should be performed simultaneously or whether a staged approach should be performed (resection of the primary tumor and after, hepatectomy, or hepatectomy first). Patients with no bowel occlusion and with extensive liver disease are advised neoadjuvant oncological therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!